Intellia Therapeutics, Inc. (NTLA), a pioneering biopharmaceutical firm specializing in CRISPR gene editing, has announced a significant financial development. The company has secured a $400 million non-dilutive senior secured term loan facility from OrbiMed, aimed at bolstering its innovative therapeutic initiatives.
Loan Structure and Milestones
The financing arrangement includes an initial $75 million disbursed at closing. Additionally, the facility provides access to $225 million in subsequent tranches, contingent upon five specific milestones primarily associated with the development of lonvoguran ziclumeran (lonvo-z). There is also potential for an extra $100 million to be unlocked during the five-year term, pending mutual agreement between Intellia and OrbiMed.
Lonvo-z: A Breakthrough Therapy
Lonvo-z represents an investigational in vivo CRISPR/Cas9 gene-editing therapy. Its goal is to achieve a permanent reduction in kallikrein levels by targeting and inactivating the KLKB1 gene through a single outpatient-administered dose. This innovative approach holds promise for patients suffering from hereditary angioedema (HAE).
Regulatory Milestones
The candidate has gained significant attention, having received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. These designations are crucial as they facilitate expedited development and review processes for therapies addressing rare diseases. Furthermore, lonvo-z has also been recognized by regulatory bodies in the U.K. and European Union, further validating its potential impact.
Financial Flexibility and Future Plans
Intellia emphasized that this debt facility enhances its financial flexibility, enabling the company to advance lonvo-z towards anticipated U.S. regulatory and commercial launch milestones for HAE patients. Such funding is vital as it allows the firm to focus its resources on innovation without diluting shareholder equity.
Additional Developments
In parallel, Intellia is making progress with another candidate, nexiguran ziclumeran (nex-z), which is currently undergoing clinical development for transthyretin amyloidosis. This reflects Intellia’s commitment to expanding its therapeutic portfolio and addressing various genetic conditions.
Support from Financial Advisors
TD Cowen has played a crucial role as the exclusive financial advisor to Intellia during this transaction. Additionally, Goodwin Procter and Covington & Burling have provided legal guidance to Intellia and OrbiMed, respectively, ensuring that all aspects of the agreement are meticulously handled.
In conclusion, Intellia Therapeutics’ recent $400 million non-dilutive debt facility marks a significant milestone in its journey towards advancing gene-editing therapies. With the financial backing to accelerate its promising candidates, the company is well-positioned to make substantial strides in treating rare genetic disorders.
- Key Takeaways:
- Intellia secured a $400 million loan facility to advance CRISPR therapies.
- Initial funding of $75 million is supplemented by milestone-based tranches.
- Lonvo-z targets hereditary angioedema and has received multiple regulatory designations.
- The facility enhances financial flexibility without diluting equity.
- Intellia continues to develop additional therapies, including nex-z for transthyretin amyloidosis.
Read more → www.rttnews.com